The last decade has seen the approval of several new biologics for the treatment of severe
asthma-targeting specific endotypes and phenotypes. This review will examine how …

Background Three anti–IL-5 pathway–directed therapies are approved for use in patients
with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are …

Background Patients with chronic obstructive pulmonary disease (COPD) with an
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …

Background Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on
therapy to standard of care for patients with severe eosinophilic asthma, has been shown in …

Background Severe asthma is a heterogeneous disease. Patients with both eosinophilic and
allergic asthma phenotypes may be eligible for treatment with mepolizumab and …

Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in
placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking …

Background Asthma exacerbations are frequent in patients with severe disease. This report
describes results from two retrospective cohort studies describing exacerbation frequency …

Background Mepolizumab and omalizumab are treatments for distinct but overlapping
severe asthma phenotypes. Objective To assess if patients eligible for both biologics but not …

Purpose The goal of this study was to assess the long-term safety and efficacy of
mepolizumab in patients with the most severe eosinophilic asthma. Methods This …